Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Human IL-7 RA&TSLP R Heterodimer Protein, Fc Tag&Fc Tag is produced by co-expression of IL-7 RA and TSLP R, has a calculated MW of 51.7 kDa (IL-7 RA) and 50.3 kDa (TSLP R). Subunit IL-7 RA is fused with a human IgG1 Fc fragment at the C-terminus and subunit TSLP R is fused with a human IgG1 Fc fragment at the C-terminus. The reducing (R) protein migrates as 60-80 kDa due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human IL-7 RA&TSLP R Heterodimer Protein, Fc Tag&Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human IL-7 RA&TSLP R Heterodimer Protein, Fc Tag&Fc Tag (Cat. No. ILR-H5255) is more than 85% and the molecular weight of this protein is around 125-140 kDa verified by SEC-MALS.
Immobilized Human IL-7 RA&TSLP R Heterodimer Protein, Fc Tag&Fc Tag (Cat. No. ILR-H5255) at 5 μg/mL (100 μL/well) can bind Human TSLP Protein, His Tag, premium grade (Cat. No. TSP-H52Hb) with a linear range of 0.4-3 ng/mL (QC tested).
Serial dilutions of Monoclonal Anti-Human TSLP Antibody, Human IgG2 were added into Human IL-7 RA&TSLP R Heterodimer Protein, Fc Tag&Fc Tag (Cat. No. ILR-H5255): Biotinylated Human TSLP, His,Avitag (Cat. No. TSP-H82Eb) binding reactions. The half maximal inhibitory concentration (IC50) is 1.09688 μg/mL (Routinely tested).
Loaded Human IL-7 RA&TSLP R Heterodimer Protein, Fc Tag&Fc Tag (Cat. No. ILR-H5255) on Protein A Biosensor, can bind Human TSLP Protein, His Tag, premium grade (Cat. No. TSP-H52Hb) with an affinity constant of 134 pM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Interleukin-7 (Revimmune SAS) | rhIL-7; CYT-107; CYT-99-007 | Phase 2 Clinical | Revimmune Inc | Prostatic Neoplasms, Castration-Resistant; Neuroectodermal Tumors, Primitive, Peripheral; Catheter-Related Infections; Rhabdomyosarcoma, Alveolar; T-Lymphocytopenia, Idiopathic CD4-Positive; Leukemia, Myeloid, Acute; Metastatic breast cancer; Hepatitis C; Ureteral Neoplasms; Urologic Neoplasms; Lymphopenia; Sarcoma; Neuroblastoma; Prostatic Neoplasms; Urethral Neoplasms; Multiple Myeloma; HIV Infections; Urinary Bladder Neoplasms; Myeloproliferative Disorders; Sepsis; Carcinoma, Transitional Cell; Coronavirus Disease 2019 (COVID-19); Mycobacterium Infections, Nontuberculous; Myelodysplastic Syndromes; Rhabdomyosarcoma, Embryonal; Hepatitis B, Chronic; Carcinoma, Renal Cell; Leukemia, Myelogenous, Chronic; Kidney Neoplasms; Skin Melanoma; Shock, Septic | Details |
Lusvertikimab | S-95011; Effi-7; OSE-217; OSE-127 | Phase 2 Clinical | Effimune | Sjogren's Syndrome; Colitis, Ulcerative | Details |
Efineptakin alfa | TJ-107; GX-I7; NT-I7 | Phase 2 Clinical | Genexine Inc | Urinary Bladder Neoplasms; Sarcoma, Kaposi; Melanoma; Carcinoma, Non-Small-Cell Lung; Laryngeal Neoplasms; Leukoencephalopathy, Progressive Multifocal; Carcinoma, Squamous Cell; Glioma; Oropharyngeal Neoplasms; Gliosarcoma; Lymphopenia; Astrocytoma; Colorectal Neoplasms; Plasmablastic Lymphoma; Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Papillomavirus Infections; Hypopharyngeal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Glioblastoma; Triple Negative Breast Neoplasms; Coronavirus Disease 2019 (COVID-19); Carcinoma, Merkel Cell; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; HIV Infections; Ovarian Neoplasms; Lymphoma, B-Cell | Details |
ASP-9801 | ASP-9801 | Phase 1 Clinical | Astellas Pharma Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
PF-06342674 | RN-168; PF-6342674; PF-06342674; ZB-168 | Phase 1 Clinical | Pfizer Inc | Diabetes Mellitus, Type 1; Multiple Sclerosis | Details |
Loco-regional B7H3 IL-7Ra CAR T Cell therapy(Chulalongkorn University) | Phase 1 Clinical | Chulalongkorn University, King Chulalongkorn Memorial Hospital | Solid tumours; Neoplasms; Brain Neoplasms; Diffuse Intrinsic Pontine Glioma | Details | |
MDK-703 | MDK-703 | Phase 1 Clinical | Medikine Inc | Solid tumours | Details |
This web search service is supported by Google Inc.